| dc.creator |
Kilicoglu, Ozge |
|
| dc.creator |
ÖZGENÇ, EMRE |
|
| dc.creator |
KARA, Ümit |
|
| dc.creator |
ATLIHAN GÜNDOĞDU, EVREN |
|
| dc.date |
2022-10-01T00:00:00Z |
|
| dc.date.accessioned |
2023-01-09T12:07:44Z |
|
| dc.date.available |
2023-01-09T12:07:44Z |
|
| dc.identifier |
c4176e73-d8fa-43b2-b4a2-7fcd215f3936 |
|
| dc.identifier |
10.1016/j.apradiso.2022.110364 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/c4176e73-d8fa-43b2-b4a2-7fcd215f3936/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/98337 |
|
| dc.description |
Monte Carlo simulation method and Nuclear Medicine MIRD method were used to evaluate the effect of ra-diopharmaceuticals on Covid-19 disease. The mean absorbed organ dose in the target organ and gamma radi-ation emitter attenuation properties such as linear attenuation coefficients, energy absorption build-up factors (EABF), exposure build-up factors (EBF), and relative dose distributions (RDD) were examined. The results showed that radiopharmaceuticals containing gamma radiation emitters which are densely ionizing charged particles induced membrane damage and produced protein damage. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Pre-clinic study of radiopharmaceutical for Covid-19 inactivation: Dose distribution with Monte Carlo Simulation |
|
| dc.type |
info:eu-repo/semantics/article |
|